Convection-enhanced Delivery

Pressure-driven bulk flow, rather than movement from the infusion site alone, carries the agent through the extracellular space, the network of spaces surrounding cells. A catheter generates a controlled pressure gradient, allowing infused material to move beyond the immediate catheter location. This mechanism explains how CED can produce broader local distribution while limiting dependence on penetration across the blood-brain barrier.

Treatment performance depends on several linked variables. Catheter placement determines where the pressure gradient is applied, infusion rate influences how the agent enters surrounding tissue, and tissue properties affect how readily bulk flow spreads. The resulting drug distribution must therefore be considered when designing a pharmacological intervention, because changing any of these factors can alter the treated region and exposure pattern.

Bypassing much of the blood-brain barrier can make localized administration relevant for agents whose access to brain tissue is limited. In pharmacology, the approach supports investigation of chemotherapeutics, biologics, gene-based agents, and neuroactive compounds. The value is not restricted to one drug class; it provides a delivery framework for testing different therapeutic strategies in brain tumors and neurological disorders.

A basic CED workflow begins with positioning a catheter in the tissue targeted for treatment, followed by controlled infusion of the selected agent. The catheter and infusion conditions establish the pressure gradient that drives movement through extracellular space. Evaluation then focuses on where the agent distributes, since placement, infusion rate, tissue properties, and the observed distribution determine whether the intended local exposure was achieved.

Researchers may consider CED when a therapeutic goal requires concentrated, localized treatment in brain tissue and limited drug penetration is a concern. The technique has relevance to brain-tumor pharmacology and neurological disorders, where investigators may study chemotherapeutics, biologics, gene-based agents, or neuroactive compounds. Its use supports both therapeutic delivery and experimental assessment of these agent classes.

CED experiments can reveal how catheter placement, infusion rate, and tissue characteristics shape the distribution of a drug or other therapeutic agent. These observations help investigators judge whether delivery extends beyond the infusion site and whether exposure remains appropriately localized. In pharmacology, such information guides therapy design and evaluation for agents intended to act within brain tissue.